The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Exact Sciences (NASDAQ:EXAS), the Madison, Wisconsin-based cancer screening and diagnostics company, announced its Q3 earnings yesterday, prompting a fall in its share price of nearly 25% in ...

its molecular residual disease and recurrence monitoring test MADISON, Wis., November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...